middle.news
Radiopharm Theranostics Doses First Patient in Pioneering BetaBart Trial
9:34am on Tuesday 24th of February, 2026 AEDT
•
Healthcare
Read Story
Radiopharm Theranostics Doses First Patient in Pioneering BetaBart Trial
9:34am on Tuesday 24th of February, 2026 AEDT
Key Points
First patient dosed in Phase 1/2a trial of 177Lu-BetaBart (RV-01)
BetaBart developed by Radiopharm Ventures joint venture with MD Anderson Cancer Center
Trial to assess safety, biodistribution, radiation dosimetry, and preliminary anti-tumor activity
Preclinical studies showed tumour shrinkage and prolonged survival in animal models
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
RADIOPHARM THERANOSTICS (ASX:RAD)
OPEN ARTICLE